Evan Walgama1, Wendy L Sacks2, Allen S Ho1. 1. Department of Surgery, Division of Otolaryngology - Head and Neck Surgery. 2. Department of Medicine, Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Abstract
PURPOSE OF REVIEW: The treatment of small, low-risk papillary thyroid carcinoma has undergone a paradigm shift, with many tumors now initially treated with active surveillance rather than upfront surgery. Further studies on patients enrolled in active surveillance have refined our knowledge of the clinical behavior of papillary thyroid microcarcinomas. RECENT FINDINGS: This article summarizes the major conclusions of landmark trials that launched active surveillance as a viable treatment option for selected patients. We discuss patient factors such as age and tumor size, the assessment of candidates for active surveillance, barriers to acceptance of active surveillance, quality of life issues, and economic considerations. SUMMARY: Active Surveillance is a viable first-line treatment option for select papillary microcarcinomas.
PURPOSE OF REVIEW: The treatment of small, low-risk papillary thyroid carcinoma has undergone a paradigm shift, with many tumors now initially treated with active surveillance rather than upfront surgery. Further studies on patients enrolled in active surveillance have refined our knowledge of the clinical behavior of papillary thyroid microcarcinomas. RECENT FINDINGS: This article summarizes the major conclusions of landmark trials that launched active surveillance as a viable treatment option for selected patients. We discuss patient factors such as age and tumor size, the assessment of candidates for active surveillance, barriers to acceptance of active surveillance, quality of life issues, and economic considerations. SUMMARY: Active Surveillance is a viable first-line treatment option for select papillary microcarcinomas.
Authors: Elisa Pasqual; Julie Ann Sosa; Yingxi Chen; Sara J Schonfeld; Amy Berrington de González; Cari M Kitahara Journal: Thyroid Date: 2022-03-15 Impact factor: 6.506
Authors: Allen S Ho; Michael Luu; Laurel Barrios; Bonnie L Balzer; Shikha Bose; Xuemo Fan; Evan Walgama; Jon Mallen-St Clair; Usman Alam; Iram Shafqat; De-Chen Lin; Yufei Chen; Jennifer E Van Eyk; Ellie G Maghami; Glenn D Braunstein; Wendy L Sacks; Zachary S Zumsteg Journal: Ann Surg Oncol Date: 2020-08-17 Impact factor: 5.344
Authors: Sandeep Kumar Parvathareddy; Abdul K Siraj; Kaleem Iqbal; Zeeshan Qadri; Saeeda O Ahmed; Maha Al-Rasheed; Ahmed A AlQatie; Saif S Al-Sobhi; Fouad Al-Dayel; Khawla S Al-Kuraya Journal: Front Endocrinol (Lausanne) Date: 2022-03-11 Impact factor: 5.555